

---

## Alligator Bioscience Q2 2025 - Progress with HLX22 and Mitazalimab

Redeye comments on Alligator Bioscience's second quarter report 2025. There has been positive news about HLX22, which we have reevaluated. Mitazalimab is essentially phase III ready. Management is working to find a partner to fund it. Alligator needs proceeds from TO13 in September to fund the rest of 2025.

**Read more and download the Research Update.**

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. [www.redeye.se/](http://www.redeye.se/)

### Attachments

---

**Alligator Bioscience Q2 2025 - Progress with HLX22 and Mitazalimab**